Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 60,547 Shares of Stock

Posted by George Bondi on Jun 8th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 60,547 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $0.40, for a total value of $24,218.80. Following the completion of the sale, the director owned 377,211 shares in the company, valued at approximately $150,884.40. This represents a 13.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $9,978.40.
On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total value of $8,831.68.
On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $13,317.75.
On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total transaction of $37,815.73.
On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,650.20.
On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.
On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.48, for a total transaction of $38,808.96.
On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total transaction of $31,936.50.
On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25.

Werewolf Therapeutics Stock Performance

NASDAQ HOWL traded down $0.01 during trading hours on Monday, hitting $0.38. The company had a trading volume of 691,037 shares, compared to its average volume of 462,670. The business has a 50 day moving average of $0.71 and a 200-day moving average of $0.73. The company has a market cap of $18.56 million, a PE ratio of -0.31 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 1-year low of $0.37 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.75.

View Our Latest Analysis on HOWL

Institutional Investors Weigh In On Werewolf Therapeutics

Several large investors have recently modified their holdings of HOWL. Bank of America Corp DE grew its position in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the period. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at about $409,000. Finally, Citadel Advisors LLC acquired a new position in shares of Werewolf Therapeutics during the third quarter worth about $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.